No increase seen in incidence of major bleeding, adverse events, or serious adverse events compared with placebo.

Older adults with adenoma at prior colonoscopy more likely to experience CRC but risk exceeded by competing risks for non-CRC death.

Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.

Psychedelic drugs could soon play a larger role in mental health care. Over the weekend, President Donald Trump signed an executive order aimed at boosting fede ...

Recommendations say clinicians should use biennial mammography for breast cancer screening in asymptomatic, average-risk women aged 50 to 74 years ...

Human-generated notes received higher overall modified Physician Documentation Quality Instrument scores than AI-generated notes across all 5 clinical cases. HealthDay News — Notes generated by ...

Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

The US Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies. Peptides are small chains of amino acids ...

Sixty-eight percent of studies exceeded benchmark of about 25% total weight loss attributable to reduction in muscle-based indices.

Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.

Based on positive phase 3 trial results, a New Drug Application will be submitted to the Food and Drug Administration for daraxonrasib.